Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A: correlation with “Inhibitor” formation
Authors:
Open Access
- 16 April 2024
- journal article
- research article
- Published by Springer Nature in Blood Research
- Vol. 59 (1) , 1-8
Abstract
Background: Development of antibodies against infused Factor VIII (FVIII) or "inhibitors" represents a major challenge following FVIII replacement therapy in patients with hemophilia A (HA). Recent studies have shown that certain cellular compartments of the immune system contribute to the production of such antibodies. Herein, we determined the frequency of class-switched CD19+IgD−CD27+/non-class-switched CD19+IgD+CD27+ memory B cell subsets and CD19+CD27hiCD38hi plasmablasts in patients with severe HA and their association with the development of inhibitors in these patients. Methods: This cross-sectional case–control study enrolled 32 patients with severe HA, including 8 with and 24 without inhibitors, and 24 healthy individuals. The frequencies of the memory B cell subsets and plasmablasts were determined using flow cytometry. Results: The frequency of CD19+IgD+CD27+ non-class-switched memory B cells was significantly lower in patients with HA (including both patients with and without inhibitors) than in healthy controls. The percentages of both CD19+IgD−CD27+ class-switched and CD19+IgD+CD27+ non-class-switched memory B cells did not differ significantly between patients with and without inhibitors. HA patients with inhibitors had significantly higher proportions of CD19+CD27hiCD38hi plasmablasts than the control group as well as the inhibitor (-) ones. No significant correlation was observed between the inhibitor levels with the percentages of memory B cell subsets and plasmablasts. Conclusion: This study is the first to demonstrate a dysregulated proportion of CD19+IgD+CD27+ non-class-switched memory B cells and CD19+CD27hiCD38hi plasmablasts in patients with severe HA. Therefore, strategies targeting memory B-cell/plasmablast differentiation may have promising outcomes in the management of inhibitor formation in patients with severe HA.Keywords
This publication has 26 references indexed in Scilit:
- Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of timeTransfusion and Apheresis Science, 2019
- Human memory B cellsLeukemia, 2016
- Strategies to target long-lived plasma cells for treating hemophilia A inhibitorsCellular Immunology, 2016
- B-cell memory against factor VIIICellular Immunology, 2016
- The generation of antibody-secreting plasma cellsNature Reviews Immunology, 2015
- Memory B cellsNature Reviews Immunology, 2015
- Haemophilia A: from mutation analysis to new therapiesNature Reviews Genetics, 2005
- Environmental and genetic factors influencing inhibitor developmentSeminars in Hematology, 2004
- The incidence of factor VIII inhibitors in patients with severe hemophilia A1995
- Incidence of development of factor VIII and factor IX inhibitors in haemophiliacsThe Lancet, 1992